CompletedNot Applicable

The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns

Egypt80 participantsStarted 2024-01-01

Plain-language summary

This aim of the study is to evaluate the effect of nebulized nitroglycerin on echocardiographic (biventricular function, pulmonary artery pressure, PDA and PFO shunting and tissue doppler imaging) and clinical parameters (Oxygen saturation index, heart rate, blood pressure, mean airway pressure, ventilation setting) in patients with PPHN.

Who can participate

Age range1 Hour – 7 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Infants ≤72 hours' old, ≥37 weeks of gestation, ≥50% FiO2 need despite lung recruitment, abnormal oxygen saturation index or echocardiographic signs of PPHN will be enrolled in the trial. Exclusion Criteria: * • Diagnosis of PPHN discovered after more than 72 hours. * Failure of used medications and need to administrate milrinone

What they're measuring

Estimation of Pulmonary artery pressure (PAP)

Timeframe: first 7 days of life

Right ventricular (RV) function in ml/kg/min

Timeframe: first 7 days of life

Left ventricular (LV)function in ml/kg/min

Timeframe: first 7 days of life

Trial details

NCT IDNCT05741229

SponsorAlexandria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-30

View on ClinicalTrials.gov More Persistent Pulmonary Hypertension of the Newborn trials